Orthocell Ltd OCC
ASX · Australia · Health Technology
AUD 0.7600-0.01 (-0.65%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) managing director and CEO Paul Anderson spoke with Proactive's Stephen Gunnion about the company recording its first Remplir sales in Thailand, expanding the global commercial footprint of its nerve repair product. Anderson said the milestone forms part of Orthocell's strategy to continually expand its international presence, with Remplir now generating revenue across seven markets including the US, Australia, New Zealand, Singapore, Hong Kong and Thailand. "We're really excited about first sales in Thailand," he said, describing the country as significant fr
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has recorded the first commercial sales of its Remplir™ nerve repair product in Thailand, extending the regenerative medicine company’s Asian footprint and opening another revenue-generating market for the product. The first sales follow Thai FDA approval...
Orthocell Ltd (ASX:OCC, OTC:ORHHF) earlier this week reported record quarterly and full-year revenue as accelerating adoption of its Remplir™ nerve repair device strengthened the company’s commercial growth outlook. Revenue reached A$3.8 million in the June quarter, up 20% from the March...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.